FindTrial
Sign In

Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients

Evaluation of Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients: a Cross-sectional Case-control Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05679648
Enrollment
100
Registered
2023-01-11
Start date
2023-06-01
Completion date
2023-12-01
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients

Keywords

hepatic steatosis, rheumatoid arthritis

Brief summary

studying the prevalence of hepatic steatosis and fibrosis in a large scale of patients with RA and healthy controls

Interventions

DIAGNOSTIC_TESTultrasonography

studying degree of steatosis

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. RA according to the American College of Rheumatology (ACR)/EULAR 2010 criteria (Aletaha et al., 2010) 2. Age≥18 years

Exclusion criteria

* History of hepatitis B and C virus infection. * Receiving hepatotoxic drugs other than RA-specific drugs. * Alcohol abuse (i30 g/day in men and ⩾20 g/day in women). * Diagnosis of Wilson's disease, α1-antitrypsin deficiency or hemochromatosis. * Autoimmune liver disease. * Cancer. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
degree of hepatic steatosis1 day during examinationdegree of hepatic steatosis by ultrasonography and Hepatic Steatosis Index.
degree of hepatic fibrosis1 day during examinationdegree of hepatic fibrosis by FIB-4 and APRI tests

Contacts

Primary ContactAmr Ahmed, Lecturer
amr.hamed@med.sohag.edu.eg02/01007065530

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026